Navigation Links
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Date:7/20/2009

PITTSBURGH, July 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.

Haloperidol Tablets are an antipsychotic typically used to reduce the symptoms of schizophrenia and uncontrollable tics and outbursts associated with Tourette syndrome. Haloperidol had total U.S. sales of approximately $21 million for the 12 months ending March 31 for the same strengths, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 119 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... a 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. ... Awards recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons ... will inspire the reader to be aware of God's direction in their lives. “Walking ... Sanford Smith, retired teacher and active church leader. , Sanford says, “I ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016 According to responses from U.S. oncologists ... (38%) of patients with non-small cell lung cancer (NSCLC), treatment ... (EGFR) genetic mutation status. The findings of the survey were ... #6067 #P3.02b ) at the 2016 World Conference on ... The survey results revealed an overall high rate ...
(Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
(Date:12/7/2016)... , Dec. 7, 2016  Lannett Company, Inc. (NYSE: ... BMO Capital Markets 2016 Prescription for Success Healthcare Conference on December ... in New York City . In ... at the Guggenheim Securities 4 th Annual Boston Healthcare Conference ... ...
Breaking Medicine Technology: